Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 2018

~ A first-in-class anti-CD25 Treg depleting antibody which enables Teff responses for optimal anti-cancer activity ~ London and Stevenage, UK – 18 April 2018:  Tusk Therapeutics, an immuno-oncology company focused on developing immune-modulating therapeutics by targeting immune cells in cancer, presented pre-clinical proof-of-concept data generated in collaboration with Cancer Research UK and University College London (UCL), relating to its anti-CD25 … Read More

Tusk Therapeutics to Present Data at AACR Annual Meeting 2018

London and Stevenage, UK – 28 March 2018: Tusk Therapeutics, an immuno-oncology company focused on developing immune-modulating therapeutics by targeting immune cells in cancer, announces today that it will deliver an oral presentation and three poster presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, … Read More